This is the authors' abstract. We don't add key points for this paper.
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Borasio et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: